First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

1. Albiges, L.
2. Tannir, N.M.
3. Burotto, M.
4. McDermott, D.
5. Plimack, E.R.
6. Barthélémy, P.
7. Porta, C.
8. Powles, T.
9. Donskov, F.
10. George, S.
11. Kollmannsberger, C.K.
12. Gurney, H.
13. Grimm, M.-O.
14. Tomita, Y.
15. Castellano, D.
16. Rini, B.I.
17. Choueiri, T.K.
18. Leung, D.
19. Saggi, S.S.
20. Lee, C.-W.
21. McHenry, M.B.
22. Motzer, R.J.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.EURURO.2021.10.001 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus